Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Annual Meeting Materials
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • FBIOP Announcements
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis

Jun 25, 2018

Mustang Bio Added to Russell 2000®, 3000® and Microcap® Indexes

Jun 25, 2018

Mustang Bio Announces Opening of CAR T Cell Therapy Manufacturing Facility in Worcester, Mass.

Jun 22, 2018

Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference

Jun 19, 2018

Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation

Jun 19, 2018

Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions

Jun 18, 2018

Avenue Therapeutics to Host Key Opinion Leader Call on Intravenous (IV) Tramadol for the Management of Postoperative Pain

Jun 06, 2018

Checkpoint Therapeutics to Participate in June Investor Conferences

Jun 04, 2018

Mustang Bio to Present at June Investor Conferences

May 31, 2018

Mustang Bio Announces Preclinical Data on Potency of its CAR T Cells in Glioblastoma Published in JCI Insight

May 30, 2018
RSS
  • Prev
    • 1...
    • 53
    • 54
    • 55
    • 56
    • 57
    • 58
    • 59
    • 60
    • 61
    • 62
    • ...71
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap